Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
8.71 x 5 9.38 x 9
Pre-market by (Cboe BZX)
8.84 -0.28 (-3.07%) 04/16/25 [NASDAQ]
8.71 x 5 9.38 x 9
Pre-market 8.84 unch (unch) 16:00 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.61
Day High
9.09
Open 9.02
Previous Close 9.12 9.12
Volume 602,300 602,300
Avg Vol 1,308,610 1,308,610
Stochastic %K 66.97% 66.97%
Weighted Alpha +30.99 +30.99
5-Day Change +0.12 (+1.38%) +0.12 (+1.38%)
52-Week Range 3.25 - 14.44 3.25 - 14.44
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 775,784
  • Shares Outstanding, K 85,064
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,000 K
  • EBIT $ -55 M
  • EBITDA $ -55 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.74

Options Overview Details

View History
  • Implied Volatility 73.93% ( -20.87%)
  • Historical Volatility 70.46%
  • IV Percentile 27%
  • IV Rank 34.85%
  • IV High 174.63% on 07/30/24
  • IV Low 20.06% on 05/01/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 523
  • Volume Avg (30-Day) 1,768
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 69,652
  • Open Int (30-Day) 60,050

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.26 +21.76%
on 04/09/25
Period Open: 9.43
10.20 -13.33%
on 03/20/25
-0.59 (-6.26%)
since 03/14/25
3-Month
7.26 +21.76%
on 04/09/25
Period Open: 10.15
10.80 -18.15%
on 01/24/25
-1.31 (-12.91%)
since 01/16/25
52-Week
3.25 +172.00%
on 04/25/24
Period Open: 4.12
14.44 -38.78%
on 12/26/24
+4.72 (+114.56%)
since 04/16/24

Most Recent Stories

More News
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

AVXL : 8.84 (-3.07%)
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

AVXL : 8.84 (-3.07%)
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

AVXL : 8.84 (-3.07%)
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 8.84 (-3.07%)
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

AVXL : 8.84 (-3.07%)
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

AVXL : 8.84 (-3.07%)
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

AVXL : 8.84 (-3.07%)
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

AVXL : 8.84 (-3.07%)
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

AVXL : 8.84 (-3.07%)
RIGL : 16.49 (-3.23%)
NVAX : 6.20 (-2.97%)
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

AVXL : 8.84 (-3.07%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 9.56
2nd Resistance Point 9.33
1st Resistance Point 9.08
Last Price 8.84
1st Support Level 8.60
2nd Support Level 8.37
3rd Support Level 8.12

See More

52-Week High 14.44
Fibonacci 61.8% 10.17
Fibonacci 50% 8.85
Last Price 8.84
Fibonacci 38.2% 7.52
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro